#USA #Ac-225 #AtomVie #IONETIX #Hamilton, ON

AtomVie Global Radiopharma Secures Strategic Supply Agreement with Ionetix

In an exciting development within the medical innovation sector, AtomVie Global Radiopharma Inc., a renowned Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, has announced a strategic partnership with Ionetix Corporation. This collaboration aims to enhance the access and supply of clinical-grade Actinium 225 (Ac-225), an essential ingredient in the evolution of targeted alpha therapies worldwide.

This supply agreement marks a significant step for AtomVie, who focuses on the development and manufacturing of cutting-edge therapeutics in the radiopharmaceutical domain. By partnering with Ionetix, AtomVie is looking to secure a reliable source of cGMP-grade Ac-225, which is pivotal for their clients' various programs aimed at treating cancer and other serious diseases. Bruno Paquin, the CEO of AtomVie, emphasized the importance of quality isotopes in advancing innovative medical solutions and expressed enthusiasm regarding the partnership's potential to meet growing global demand.

As AtomVie prepares to open its new, state-of-the-art manufacturing facility, the demand for high-quality isotopes has surged. The new facility will bolster AtomVie’s ability to support clients from initial research stages through clinical trials, thereby ensuring a streamlined path toward effective treatments. This collaboration with Ionetix not only consolidates AtomVie’s existing service portfolio but also empowers the company to cater to the increasing pipeline of alpha-based therapeutic candidates.

Ionetix has established itself as a leader in the cyclotron technology sphere, providing rare radioisotopes used in both diagnostic and therapeutic settings. Their commitment to delivering high-purity Ac-225 signifies a dedication to enhancing patient care by ensuring that healthcare providers have access to the necessary materials. David Eve, the Vice President of Medical Affairs at Ionetix, noted that by supplying Ac-225, they are contributing to a more scalable path for companies eager to bring pioneering therapies to market.

The collaboration symbolizes a unification of resources aimed at pushing forward the boundaries of what is achievable in the field of targeted radiopharmaceuticals. As AtomVie integrates a stable supply network of isotopes directly into its development and manufacturing processes, the intent is to enhance service delivery for clients, ensuring that their programs are not just aspirational but actively progressing towards clinical application.

Furthermore, this partnership is expected to reinforce both organizations' shared goal of advancing the frontiers of radiopharmaceutical innovation. The global healthcare landscape demands continual evolution, particularly in areas relying on advanced radiopharmaceuticals for patient treatment. The increasing incidence of diseases like cancer calls for novel therapeutic approaches, and partnerships such as that between AtomVie and Ionetix are pivotal in actualizing these innovations.

In summary, this strategic alliance is a promising development in enhancing the pipeline of Ac-225-derived assets, reinforcing the notion that collaboration is crucial in navigating the intricacies of modern medicine. As both companies work closely together, they are not only investing in their futures but also directly impacting the lives of patients who rely on these advanced therapies.

About AtomVie Global Radiopharma

AtomVie is recognized globally as a leading CDMO specializing in the GMP production and distribution of clinical and commercial radiopharmaceuticals. The company offers a comprehensive suite of scientific, technical, regulatory, and logistics services, boasting robust infrastructure supporting the development from clinical trials to commercial markets. Serving clients across 28 countries, AtomVie stands at the forefront of radiopharmaceutical manufacturing, and with a new, cutting-edge facility set to be operational in early 2026, they are poised to further enhance their offerings.

About Ionetix Corporation

Ionetix is a pioneer in providing innovative solutions for the production of scarce radioisotopes essential for diagnostic and therapeutic applications. By leveraging advanced cyclotron technology, Ionetix supplies high-purity isotopes, facilitating the growth of targeted alpha therapies through a comprehensive distribution network and top-tier manufacturing services.